Thursday, October 18, 2012
Publication and contact
Mouse model for
nonalcoholic fatty liver disease
A mouse model of
nonalcoholic fatty liver disease (NAFLD) could be used to help identify
therapeutics. The I148M variant of patatin-like phospholipase domain containing 3
is a risk factor for NAFLD. Mice that overexpressed the I148M variant of
human PNPLA3 in the liver had a fatty liver phenotype and showed other
metabolic features of NAFLD. In these mice, liver secretions showed less
hydrolysis and higher levels of disease-causing triacylglycerol than liver
secretions from wild-type controls. Next steps could include using the model
to evaluate therapeutic candidates.
Published online Oct. 18, 2012
Patent and licensing status
Li, J.Z. et al. J. Clin.
Invest.; published online Oct. 1, 2012;
Contact: Helen H. Hobbs, The University of Texas
Southwestern Medical Center, Dallas, Texas
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]